Leveraged Finance Fights Melanoma
September 30, 2021 | 6:30 pm ET.
Join us for cocktails & hors d’oeuvres as LFFM returns in-person in New York!
Museum of Modern Art
18 West 54th Street
New York, NY
As LFFM enters its 10th year, we are tremendously grateful for the nearly $14 million raised by LFFM to advance 21 grants for cutting-edge melanoma research. LFFM’s support of MRA has not only helped improve survivorship for melanoma patients, but has allowed MRA to champion revolutions in immunotherapies, targeted therapies, and novel combinations that are now being used in many other cancer types
Please email Janine Rauscher with any questions or to sponsor.
2021 Event Chairs: Clare Bailhé (MidCap Financial), Brendan Dillon (UBS), Kerry Dolan (Brinley Partners), Lee Grinberg (Elliott Management), George Mueller (KKR), AJ Murphy (40 North), Geoff Oltmans (Silver Lake), Jeff Rowbottom (Iron Park Capital), Ian Schuman (Latham & Watkins), Cade Thompson (KKR), Trevor Watt (Hellman & Friedman), & Eric Wedel (Kirkland & Ellis)
About LFFM: Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Mike Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.
The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom of PSP Investments and Brendan Dillon of UBS—both of whom combatted melanoma— the LFFM event has raised more than $14 million that goes directly to research.
Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 13 of the 15 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers.